Our team recently published Part II in a 3-part series aimed at helping drug manufactures gain an updated view of VA and DOD drug...

Bottom Line: The VA's updated presumptive conditions list expanding coverage for Gulf War and Post-9/11 veterans necessitates...

Bottom Line: Serving 2.8 million veterans at a $23.9 billion cost in FY2023, the VA Community Care Program expands healthcare access by...

Bottom Line: The VA's short-term community pharmacy Rx access isn't as open-ended as many assume. The Urgent/Emergent formulary contains...

Bottom Line: The VA formulary balances quality of care with cost-effectiveness by considering clinical evidence, veteran needs, and...

Bottom Line: The Veterans Community Care Program, a program that allows veterans to receive healthcare from community providers, utilizes...

Bottom Line: Manufacturers of biosimilars should explore and emphasize the opportunity to enhance the affordability and accessibility of...

Bottom Line: The Defense Logistic Agency (DLA) Electronic Catalog (ECAT) is an online platform that streamlines the procurement of...

Bottom Line: While an FSS contract ensures a product's availability to Federal agencies, formulary status is determined independently by...

Bottom Line: DOD is often the first P&T review following FDA approval and its meeting minutes are public - yet, a lot of manufacturers...

Bottom line: The VA Epilepsy Centers of Excellence (ECoE) network provide comprehensive care for veterans with epilepsy and other seizure...

Bottomline: There is one formulary, the TRICARE Uniform Formulary, that applies to both Military Treatment Facilities (MTFs) and retail...